Nivolumab and Chemotherapy for Mesothelioma is Focus of New Trial – Surviving Mesothelioma

Researchers in Germany are recruiting patients for a trial of nivolumab and chemotherapy for pleural mesothelioma patients who have had surgery.
Nivolumab (Opdivo) is an immunotherapy drug similar to pembrolizumab (Keytruda). It blocks a protein that helps mesothelioma cells hide from the immune system. Nivolumab is most often used for patients with non-small cell lung cancer.
The multicenter German study will test if a combination of nivolumab and chemotherapy can help keep tumors from growing…

Click here to view the original article.